APO RESEARCH · REPORT
Veterinary Lyme Disease Vaccines
Veterinary Lyme disease vaccines are companion-animal biologics designed to reduce the probability and magnitude of infection with Borreliella (Borrelia) burgdorferi sensu lato after exposure to competent Ixodes ticks. The commercial and clinical category is functionally canine; a limited feline line exists in parts of Europe, and there are no licensed equine or food-animal products. Use is risk-based rather than core and is paired with acaricides and environmental tick management. The etiologic agents are host-adapted spirochetes maintained in an enzootic cycle linking small mammals and certain birds with hard ticks. Larval and nymphal Ixodes acquire organisms during a blood meal, retain them transstadially, and transmit during subsequent feeding. Within unfed ticks, spirochetes occupy a vector-adapted state; attachment and feeding trigger a transcriptional switch toward mammalian-phase biology, down-regulating vector-phase genes and up-regulating mammalian-phase genes as organisms exit the midgut for the salivary glands. Geographically, veterinary and human hotspots mirror vector ranges: I. scapularis in the northeastern and upper midwestern United States with a coastal Pacific belt under I. pacificus; I. ricinus across temperate Europe; and I. persulcatus across northern Eurasia. North American canine disease is dominated by B. burgdorferi sensu stricto, whereas B. garinii and B. afzelii contribute materially in Europe and the UK; stable natural foci also occur across parts of northeastern Asia.
Product & engineering
Understand the product.
Veterinary Lyme disease vaccines are companion-animal biologics designed to reduce the probability and magnitude of infection with Borreliella (Borrelia) burgdorferi sensu lato after exposure to competent Ixodes ticks. The commercial and clinical category is functionally canine; a limited feline line exists in parts of Europe, and there are no licensed equine or food-animal products. Use is risk-based rather than core and is paired with acaricides and environmental tick management. The etiologic agents are host-adapted spirochetes maintained in an enzootic cycle linking small mammals and certain birds with hard ticks. Larval and nymphal Ixodes acquire organisms during a blood meal, retain them transstadially, and transmit during subsequent feeding. Within unfed ticks, spirochetes occupy a vector-adapted state; attachment and feeding trigger a transcriptional switch toward mammalian-phase biology, down-regulating vector-phase genes and up-regulating mammalian-phase genes as organisms exit the midgut for the salivary glands. Geographically, veterinary and human hotspots mirror vector ranges: I. scapularis in the northeastern and upper midwestern United States with a coastal Pacific belt under I. pacificus; I. ricinus across temperate Europe; and I. persulcatus across northern Eurasia. North American canine disease is dominated by B. burgdorferi sensu stricto, whereas B. garinii and B. afzelii contribute materially in Europe and the UK; stable natural foci also occur across parts of northeastern Asia.
Two vaccine platforms encompass licensed products and map onto distinct biological bottlenecks. Bacterins are inactivated whole-cell preparations that present broad antigenic repertoires; in commerce they are typically bivalent by strain in North America and trivalent in Europe to align with regional sensu lato diversity. Recombinant protein subunits are defined-composition formulations built around outer-surface lipoproteins with established protective correlates. One branch uses lipidated outer surface protein A (OspA) as a single antigen; the other pairs OspA with an engineered OspC chimeric epitope protein (“chimeritope”) that concatenates linear epitopes from multiple OspC types to extend breadth. Mechanistically, anti-OspA antibodies act mainly within the feeding tick midgut, binding OspA on vector-phase organisms and impeding survival and transmission, whereas anti-OspC antibodies act in the early mammalian window at the bite site and draining tissues, promoting neutralization and opsonophagocytic clearance before hematogenous dissemination. The responses are temporally complementary and address distinct transmission bottlenecks.
Antigen-level detail underpins both design and diagnostics. OspA is a lipidated outer-membrane lipoprotein abundantly expressed by unfed tick-phase organisms; protective B-cell epitopes cluster toward the C-terminal domain, the locus of canonical neutralizing monoclonals, and OspA is down-regulated during feeding and host entry, which explains its principal value at the vector interface and its pairing with mammalian-phase antigens in some subunits. OspC is a smaller, dimeric lipoprotein whose transcription is strongly induced during tick feeding and the first days of mammalian infection; it contributes to early tissue invasion and complement interactions and is a dominant target of early humoral responses. OspC is highly polymorphic and partitioned into dozens of phylogenetic types maintained by recombination and frequency-dependent selection; antibody responses are largely type-specific and cross-protection is limited. Chimeritope designs address this constraint by assembling immunodominant linear segments—classically from the variable L5 and H5 regions—drawn from representative OspC types into a single recombinant antigen capable of broad binding across OspC diversity. In genomic context, OspA is encoded on lp54, OspC on cp26, and the vls cassette system on lp28-1 underpins antigenic variation during persistence; this plasmid architecture explains phase-specific expression and immune evasion. Serology follows from these rules: antibodies to the VlsE-derived C6 peptide track natural infection and are not induced by OspA-only vaccination, whereas bacterins and OspC-containing subunits broaden antibody profiles and require assay selection and clinical correlation to distinguish vaccine responses from infection.
Historically, the category progressed from whole-cell to defined-antigen formulations. Early licensed canine products in the 1990s were formalin-inactivated cell-lysate bacterins (e.g., LymeVax and Galaxy Lyme). The next phase introduced recombinant OspA subunits to avoid nonessential antigens and focus on vector-phase blockade. From the mid-2010s, OspA plus OspC chimeritope formulations appeared, targeting both the tick midgut and the early mammalian phase while addressing OspC’s strong polymorphism. This trajectory reflects a shift from breadth via whole-cell antigen overload to breadth-with-specificity via defined antigens, with corresponding gains in compositional clarity and mechanistic alignment to transmission biology.
The global burden aligns with vector ecology and surveillance intensity. In the United States, highest veterinary and human risk occurs from the mid-Atlantic through New England and the upper Midwest, with additional foci on the Pacific coast; in Canada, risk concentrates in southern Ontario, Québec, the Maritimes, and expanding prairie and coastal belts. In Europe, risk spans the UK and Ireland, the Benelux and Alpine corridors, Germany and Poland, the Baltics and Scandinavia, and northern Mediterranean foothills where I. ricinus is established. Across northern Eurasia, I. persulcatus supports foci from northeastern Europe through western Russia into Siberia and parts of the Far East. Outside North America and Europe many jurisdictions do not license canine Lyme vaccines and rely on acaricides and exposure management.
Current products in commerce resolve to a short, well-defined list whose differences are meaningful at the level of antigen strategy, breadth, and evidentiary posture rather than dose logistics. VANGUARD® crLyme is an OspA plus OspC chimeritope subunit; the OspC component presents a panel of linear epitopes drawn from diverse OspC types, aiming to maintain binding breadth across local OspC ecologies while pairing vector-phase interception with early mammalian-phase neutralization. This defined-composition approach yields strong titers to both components, challenge-model protection across infection and histopathology endpoints, and an extended duration-of-immunity label in its home market; trade-offs include broader serologic footprints that can complicate interpretation on certain assays and a dependence on epitope selection relative to regional OspC phylogeny. RECOMBITEK® Lyme (rLyme) is a non-adjuvanted, lipidated OspA subunit that emphasizes a tight antigen profile and a vector-interface mechanism; benefits include minimal extraneous proteins and preserved interpretability of C6-based diagnostics, while constraints center on the absence of an explicit OspC component, making timely transmission interception and booster maintenance central to performance. Nobivac® Lyme is a bivalent bacterin built around two B. burgdorferi sensu stricto strains selected to emphasize OspA and OspC expression characteristics; it delivers broad borreliacidal responses with long field experience and a 12-month duration label in its home market, balanced against the inherent complexity of whole-cell formulations and limited public standardization of OspC expression in production cultures. Duramune® Lyme and Ultra Duramune® Lyme—and their successor branding TruCan™ Lyme and TruCan™ Ultra Lyme—are bivalent bacterins positioned for breadth and for integration into combination presentations with Leptospira or broader canine cores; strengths include robust whole-cell immunogenic breadth and portfolio flexibility, while constraints mirror the bacterin class: extraneous-antigen overhead, culture-stage expression variability, and the fact that reduced fill volume by itself does not evidence superior protection. In Europe and the UK, Borrelym 3 and Merilym 3 are trivalent bacterins that include B. afzelii, B. garinii, and B. burgdorferi sensu stricto to match regional sensu lato diversity; they are well aligned to I. ricinus regions but, as whole-cell products, share the class’s compositional constraints and have limited public species-specific protection data versus each included sensu lato species. Within the same manufacturer’s portfolio, Biocan B is a canine bacterin used where national registrations permit, and Biofel B is a niche feline bacterin available in limited jurisdictions; both follow the bacterin paradigm with corresponding advantages in breadth and constraints in specificity and transparency.
Taken together, veterinary Lyme disease vaccines are best understood as a small, mechanism-anchored category defined by two platforms, two principal antigens with distinct temporal loci of action, and a finite set of market models whose antigen strategies map directly onto transmission biology. Bacterins trade compositional complexity for breadth; OspA subunits trade breadth for precision at the vector interface; OspA plus OspC chimeritopes aim to recapture breadth with defined antigens by spanning vector and early mammalian phases. Regional epidemiology and OspC phylogeny shape optimal fit, diagnostics must be interpreted with platform awareness, and program value is maximized when vaccination is integrated with acaricides and exposure management in dogs genuinely at risk.
Selected research
Industry Research
Veterinary Lyme Disease Vaccines Industry Research Report 2026
Market perspective
Veterinary Lyme disease vaccines are companion-animal biologics designed to reduce the probability and magnitude of infection with Borreliella (Borrelia) burgdorferi sensu lato after exposure to competent Ixodes ticks. The commercial and clinical category is functionally canine; a limited feline line exists in parts of Europe, and there are no licensed equine or food-animal products. Use is risk-based rather than core and is paired with acaricides and environmental tick management. The etiologic agents are host-adapted spirochetes maintained in an enzootic cycle linking small mammals and certain birds with hard ticks. Larval and nymphal Ixodes acquire organisms during a blood meal, retain them transstadially, and transmit during subsequent feeding. Within unfed ticks, spirochetes occupy a vector-adapted state; attachment and feeding trigger a transcriptional switch toward mammalian-phase biology, down-regulating vector-phase genes and up-regulating mammalian-phase genes as organisms exit the midgut for the salivary glands. Geographically, veterinary and human hotspots mirror vector ranges: I. scapularis in the northeastern and upper midwestern United States with a coastal Pacific belt under I. pacificus; I. ricinus across temperate Europe; and I. persulcatus across northern Eurasia. North American canine disease is dominated by B. burgdorferi sensu stricto, whereas B. garinii and B. afzelii contribute materially in Europe and the UK; stable natural foci also occur across parts of northeastern Asia.
Two vaccine platforms encompass licensed products and map onto distinct biological bottlenecks. Bacterins are inactivated whole-cell preparations that present broad antigenic repertoires; in commerce they are typically bivalent by strain in North America and trivalent in Europe to align with regional sensu lato diversity. Recombinant protein subunits are defined-composition formulations built around outer-surface lipoproteins with established protective correlates. One branch uses lipidated outer surface protein A (OspA) as a single antigen; the other pairs OspA with an engineered OspC chimeric epitope protein (“chimeritope”) that concatenates linear epitopes from multiple OspC types to extend breadth. Mechanistically, anti-OspA antibodies act mainly within the feeding tick midgut, binding OspA on vector-phase organisms and impeding survival and transmission, whereas anti-OspC antibodies act in the early mammalian window at the bite site and draining tissues, promoting neutralization and opsonophagocytic clearance before hematogenous dissemination. The responses are temporally complementary and address distinct transmission bottlenecks.
Antigen-level detail underpins both design and diagnostics. OspA is a lipidated outer-membrane lipoprotein abundantly expressed by unfed tick-phase organisms; protective B-cell epitopes cluster toward the C-terminal domain, the locus of canonical neutralizing monoclonals, and OspA is down-regulated during feeding and host entry, which explains its principal value at the vector interface and its pairing with mammalian-phase antigens in some subunits. OspC is a smaller, dimeric lipoprotein whose transcription is strongly induced during tick feeding and the first days of mammalian infection; it contributes to early tissue invasion and complement interactions and is a dominant target of early humoral responses. OspC is highly polymorphic and partitioned into dozens of phylogenetic types maintained by recombination and frequency-dependent selection; antibody responses are largely type-specific and cross-protection is limited. Chimeritope designs address this constraint by assembling immunodominant linear segments—classically from the variable L5 and H5 regions—drawn from representative OspC types into a single recombinant antigen capable of broad binding across OspC diversity. In genomic context, OspA is encoded on lp54, OspC on cp26, and the vls cassette system on lp28-1 underpins antigenic variation during persistence; this plasmid architecture explains phase-specific expression and immune evasion. Serology follows from these rules: antibodies to the VlsE-derived C6 peptide track natural infection and are not induced by OspA-only vaccination, whereas bacterins and OspC-containing subunits broaden antibody profiles and require assay selection and clinical correlation to distinguish vaccine responses from infection.
Read the full market overview
Historically, the category progressed from whole-cell to defined-antigen formulations. Early licensed canine products in the 1990s were formalin-inactivated cell-lysate bacterins (e.g., LymeVax and Galaxy Lyme). The next phase introduced recombinant OspA subunits to avoid nonessential antigens and focus on vector-phase blockade. From the mid-2010s, OspA plus OspC chimeritope formulations appeared, targeting both the tick midgut and the early mammalian phase while addressing OspC’s strong polymorphism. This trajectory reflects a shift from breadth via whole-cell antigen overload to breadth-with-specificity via defined antigens, with corresponding gains in compositional clarity and mechanistic alignment to transmission biology.
The global burden aligns with vector ecology and surveillance intensity. In the United States, highest veterinary and human risk occurs from the mid-Atlantic through New England and the upper Midwest, with additional foci on the Pacific coast; in Canada, risk concentrates in southern Ontario, Québec, the Maritimes, and expanding prairie and coastal belts. In Europe, risk spans the UK and Ireland, the Benelux and Alpine corridors, Germany and Poland, the Baltics and Scandinavia, and northern Mediterranean foothills where I. ricinus is established. Across northern Eurasia, I. persulcatus supports foci from northeastern Europe through western Russia into Siberia and parts of the Far East. Outside North America and Europe many jurisdictions do not license canine Lyme vaccines and rely on acaricides and exposure management.
Current products in commerce resolve to a short, well-defined list whose differences are meaningful at the level of antigen strategy, breadth, and evidentiary posture rather than dose logistics. VANGUARD® crLyme is an OspA plus OspC chimeritope subunit; the OspC component presents a panel of linear epitopes drawn from diverse OspC types, aiming to maintain binding breadth across local OspC ecologies while pairing vector-phase interception with early mammalian-phase neutralization. This defined-composition approach yields strong titers to both components, challenge-model protection across infection and histopathology endpoints, and an extended duration-of-immunity label in its home market; trade-offs include broader serologic footprints that can complicate interpretation on certain assays and a dependence on epitope selection relative to regional OspC phylogeny. RECOMBITEK® Lyme (rLyme) is a non-adjuvanted, lipidated OspA subunit that emphasizes a tight antigen profile and a vector-interface mechanism; benefits include minimal extraneous proteins and preserved interpretability of C6-based diagnostics, while constraints center on the absence of an explicit OspC component, making timely transmission interception and booster maintenance central to performance. Nobivac® Lyme is a bivalent bacterin built around two B. burgdorferi sensu stricto strains selected to emphasize OspA and OspC expression characteristics; it delivers broad borreliacidal responses with long field experience and a 12-month duration label in its home market, balanced against the inherent complexity of whole-cell formulations and limited public standardization of OspC expression in production cultures. Duramune® Lyme and Ultra Duramune® Lyme—and their successor branding TruCan™ Lyme and TruCan™ Ultra Lyme—are bivalent bacterins positioned for breadth and for integration into combination presentations with Leptospira or broader canine cores; strengths include robust whole-cell immunogenic breadth and portfolio flexibility, while constraints mirror the bacterin class: extraneous-antigen overhead, culture-stage expression variability, and the fact that reduced fill volume by itself does not evidence superior protection. In Europe and the UK, Borrelym 3 and Merilym 3 are trivalent bacterins that include B. afzelii, B. garinii, and B. burgdorferi sensu stricto to match regional sensu lato diversity; they are well aligned to I. ricinus regions but, as whole-cell products, share the class’s compositional constraints and have limited public species-specific protection data versus each included sensu lato species. Within the same manufacturer’s portfolio, Biocan B is a canine bacterin used where national registrations permit, and Biofel B is a niche feline bacterin available in limited jurisdictions; both follow the bacterin paradigm with corresponding advantages in breadth and constraints in specificity and transparency.
Taken together, veterinary Lyme disease vaccines are best understood as a small, mechanism-anchored category defined by two platforms, two principal antigens with distinct temporal loci of action, and a finite set of market models whose antigen strategies map directly onto transmission biology. Bacterins trade compositional complexity for breadth; OspA subunits trade breadth for precision at the vector interface; OspA plus OspC chimeritopes aim to recapture breadth with defined antigens by spanning vector and early mammalian phases. Regional epidemiology and OspC phylogeny shape optimal fit, diagnostics must be interpreted with platform awareness, and program value is maximized when vaccination is integrated with acaricides and exposure management in dogs genuinely at risk.
The global Veterinary Lyme Disease Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Veterinary Lyme Disease Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Veterinary Lyme Disease Vaccines is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
The Asia Pacific market for Veterinary Lyme Disease Vaccines is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Veterinary Lyme Disease Vaccines include Zoetis, Boehringer Ingelheim, Elanco, Merck Animal Health and Bioveta, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Veterinary Lyme Disease Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (k doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k doses) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Veterinary Lyme Disease Vaccines Market by Company
Zoetis
Boehringer Ingelheim
Elanco
Merck Animal Health
Bioveta
Veterinary Lyme Disease Vaccines Segment by Type
Recombinant Subunit Vaccines
Bacterin Vaccines
Veterinary Lyme Disease Vaccines Segment by Application
Canine
Feline
Veterinary Lyme Disease Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Veterinary Lyme Disease Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Veterinary Lyme Disease Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Veterinary Lyme Disease Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Veterinary Lyme Disease Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Veterinary Lyme Disease Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Veterinary Lyme Disease Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Recombinant Subunit Vaccines
- Bacterin Vaccines
Applications
- Canine
- Feline
Companies covered
- Zoetis
- Boehringer Ingelheim
- Elanco
- Merck Animal Health
- Bioveta
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Veterinary Lyme Disease Vaccines Market Size (2021-2032)
- 2.2.2 Global Veterinary Lyme Disease Vaccines Sales (2021-2032)
- 2.2.3 Global Veterinary Lyme Disease Vaccines Market Average Price (2021-2032)
- 2.3 Veterinary Lyme Disease Vaccines by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Recombinant Subunit Vaccines
- 2.3.3 Bacterin Vaccines
- 2.4 Veterinary Lyme Disease Vaccines by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Canine
- 2.4.3 Feline
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Veterinary Lyme Disease Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Veterinary Lyme Disease Vaccines Sales (k doses) of Manufacturers (2021-2026)
- 3.3 Global Veterinary Lyme Disease Vaccines Revenue of Manufacturers (2021-2026)
- 3.4 Global Veterinary Lyme Disease Vaccines Average Price by Manufacturers (2021-2026)
- 3.5 Global Veterinary Lyme Disease Vaccines Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Veterinary Lyme Disease Vaccines, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Veterinary Lyme Disease Vaccines, Product Type & Application
- 3.8 Global Manufacturers of Veterinary Lyme Disease Vaccines, Established Date
- 3.9 Global Veterinary Lyme Disease Vaccines Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Zoetis
- 4.1.1 Zoetis Company Information
- 4.1.2 Zoetis Business Overview
- 4.1.3 Zoetis Veterinary Lyme Disease Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Zoetis Veterinary Lyme Disease Vaccines Product Portfolio
- 4.1.5 Zoetis Recent Developments
- 4.2 Boehringer Ingelheim
- 4.2.1 Boehringer Ingelheim Company Information
- 4.2.2 Boehringer Ingelheim Business Overview
- 4.2.3 Boehringer Ingelheim Veterinary Lyme Disease Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Boehringer Ingelheim Veterinary Lyme Disease Vaccines Product Portfolio
- 4.2.5 Boehringer Ingelheim Recent Developments
- 4.3 Elanco
- 4.3.1 Elanco Company Information
- 4.3.2 Elanco Business Overview
- 4.3.3 Elanco Veterinary Lyme Disease Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Elanco Veterinary Lyme Disease Vaccines Product Portfolio
- 4.3.5 Elanco Recent Developments
- 4.4 Merck Animal Health
- 4.4.1 Merck Animal Health Company Information
- 4.4.2 Merck Animal Health Business Overview
- 4.4.3 Merck Animal Health Veterinary Lyme Disease Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck Animal Health Veterinary Lyme Disease Vaccines Product Portfolio
- 4.4.5 Merck Animal Health Recent Developments
- 4.5 Bioveta
- 4.5.1 Bioveta Company Information
- 4.5.2 Bioveta Business Overview
- 4.5.3 Bioveta Veterinary Lyme Disease Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Bioveta Veterinary Lyme Disease Vaccines Product Portfolio
- 4.5.5 Bioveta Recent Developments
5 Global Veterinary Lyme Disease Vaccines Market Scenario by Region
- 5.1 Global Veterinary Lyme Disease Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Veterinary Lyme Disease Vaccines Sales by Region: 2021-2032
- 5.2.1 Global Veterinary Lyme Disease Vaccines Sales by Region: 2021-2026
- 5.2.2 Global Veterinary Lyme Disease Vaccines Sales by Region: 2027-2032
- 5.3 Global Veterinary Lyme Disease Vaccines Revenue by Region: 2021-2032
- 5.3.1 Global Veterinary Lyme Disease Vaccines Revenue by Region: 2021-2026
- 5.3.2 Global Veterinary Lyme Disease Vaccines Revenue by Region: 2027-2032
- 5.4 North America Veterinary Lyme Disease Vaccines Market Facts & Figures by Country
- 5.4.1 North America Veterinary Lyme Disease Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Veterinary Lyme Disease Vaccines Sales by Country (2021-2032)
- 5.4.3 North America Veterinary Lyme Disease Vaccines Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Veterinary Lyme Disease Vaccines Market Facts & Figures by Country
- 5.5.1 Europe Veterinary Lyme Disease Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Veterinary Lyme Disease Vaccines Sales by Country (2021-2032)
- 5.5.3 Europe Veterinary Lyme Disease Vaccines Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Veterinary Lyme Disease Vaccines Market Facts & Figures by Country
- 5.6.1 Asia Pacific Veterinary Lyme Disease Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Veterinary Lyme Disease Vaccines Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Veterinary Lyme Disease Vaccines Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Veterinary Lyme Disease Vaccines Market Facts & Figures by Country
- 5.7.1 South America Veterinary Lyme Disease Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Veterinary Lyme Disease Vaccines Sales by Country (2021-2032)
- 5.7.3 South America Veterinary Lyme Disease Vaccines Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Veterinary Lyme Disease Vaccines Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Veterinary Lyme Disease Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Veterinary Lyme Disease Vaccines Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Veterinary Lyme Disease Vaccines Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Veterinary Lyme Disease Vaccines Sales by Type (2021-2032)
- 6.1.1 Global Veterinary Lyme Disease Vaccines Sales by Type (2021-2032) & (k doses)
- 6.1.2 Global Veterinary Lyme Disease Vaccines Sales Market Share by Type (2021-2032)
- 6.2 Global Veterinary Lyme Disease Vaccines Revenue by Type (2021-2032)
- 6.2.1 Global Veterinary Lyme Disease Vaccines Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Veterinary Lyme Disease Vaccines Revenue Market Share by Type (2021-2032)
- 6.3 Global Veterinary Lyme Disease Vaccines Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Veterinary Lyme Disease Vaccines Sales by Application (2021-2032)
- 7.1.1 Global Veterinary Lyme Disease Vaccines Sales by Application (2021-2032) & (k doses)
- 7.1.2 Global Veterinary Lyme Disease Vaccines Sales Market Share by Application (2021-2032)
- 7.2 Global Veterinary Lyme Disease Vaccines Revenue by Application (2021-2032)
- 7.2.1 Global Veterinary Lyme Disease Vaccines Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Veterinary Lyme Disease Vaccines Revenue Market Share by Application (2021-2032)
- 7.3 Global Veterinary Lyme Disease Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Veterinary Lyme Disease Vaccines Value Chain Analysis
- 8.1.1 Veterinary Lyme Disease Vaccines Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Veterinary Lyme Disease Vaccines Production Mode & Process
- 8.2 Veterinary Lyme Disease Vaccines Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Veterinary Lyme Disease Vaccines Distributors
- 8.2.3 Veterinary Lyme Disease Vaccines Customers
9 Global Veterinary Lyme Disease Vaccines Analyzing Market Dynamics
- 9.1 Veterinary Lyme Disease Vaccines Industry Trends
- 9.2 Veterinary Lyme Disease Vaccines Industry Drivers
- 9.3 Veterinary Lyme Disease Vaccines Industry Opportunities and Challenges
- 9.4 Veterinary Lyme Disease Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst